Management of Pulmonary Fibrosis from COVID-19 Pneumonia with Nintedanib

Main Article Content

Sawang Saenghirunvattana
Thanis Saksirinukul
Thiti Sricharoenchai

Abstract

OBJECTIVES: To propose the benefit of antifibrotic agent, nintedanib, in the treatment of lung fibrosis from SARS-CoV-2 Coronavirus 2019 (COVID-19) pneumonia, based on experience at Bangkok Hospital Headquarters, Bangkok, Thailand.


MATERIALS AND METHODS: Data from patients who developed lung fibrosis post COVID-19 pneumonia during 2020-2022 at our institute, all developed severe pneumonia, was analyzed, including clinical signs and symptoms, imaging findings, O2 saturation: at room air and during 6 minutes’ walk, and response to treatment.


RESULTS: Among 10 patients with COVID-19 lung fibrosis who received steroids, remdesivir and nintedanib; 2 patients (20%) expired, 7 patients (70%) were back to normal within 3 months, and 1 patient (10%) was able to walk with oxygen 2 liter per minute (LPM) after 7 months.


CONCLUSION: An antifibrotic agent, such as nintedanib, could improve lung fibrosis from COVID-19 pneumonia.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Saenghirunvattana S, Saksirinukul T, Sricharoenchai T. Management of Pulmonary Fibrosis from COVID-19 Pneumonia with Nintedanib. BKK Med J [Internet]. 2022 Sep. 30 [cited 2022 Dec. 4];18(2):102. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/258947
Section
Original Article

References

Mamun SMAA, Jahan R, Islam QT, et al. Rational of using common antifibrotic therapy in post COVID fibrosis. J Med 2021;22(1):46-50. ID: covidwho-1059839

Chung MP, Park MS, Oh IJ, et al. Safety and efficacy of perfenidine in advanced idiopathic pulmonary fibrosis. Adv Ther 2020;37(5);2303-16. doi: 10.1007/s12325-020-01328-8.

Thille AW, Estaban A, Fernandez-Segoviano P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: A prospective cohort study of clinical autopsies. Lancet Respir Med 2013;1(5):395-401. doi: 10.1016/S2213-2600(13)70053-5.

Umemaru Y, Mitsuyama Y, Minami K, et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study. Int J Infect Dis 2021;108:454-60. doi: 10.1016/j.ijid.2021.05.055.

Ogata H, Nakagawa T, Sakoda S, et al. Nintedanib treatment for pulmonary fibrosis aftercoronavirus 2019. Respirol Case Rep 2021;9(5):e00744. doi: 10.1002/rcr2.744.

Vitug LC, Santiaguel J. Nintedanib as in adjunct treatment in improving lung function of post-COVID-19 pulmonary fibrosis in an elderly patient: a case report. Chest 2021:160(4):A2166. doi: 10.1016/j.chest.2021.07.1914

Singh P, Behera D, Gupta S, et al. Nintedanib vs perfenidone in the management of COVID-19 lung fibrosis: A single center study. JRCPE 2022:1-6. doi: 10.1177/14782715221103402